CM-Glucan™ Nu (Carboxymethyl Yeast Beta-Glucan)

Saccharomyces cerevisiae
Evidence Level
Limited
2 Clinical Trials
3 Documented Benefits
2/5 Evidence Score

CM-Glucan™ Nu is Mibelle's water-soluble carboxymethylated beta-1,3/1,6-glucan from baker's yeast (Saccharomyces cerevisiae), an oral immune 'trainer' marketed for resilience and airborne-allergy symptom relief. Its own branded trial was published in a non-PubMed-indexed journal, but the broader yeast beta-glucan class has solid randomized evidence for immune support. Honest framing: judge CM-Glucan Nu on the strong beta-glucan class evidence plus a manufacturer trial rather than on independently indexed brand-specific data.

Studied Dose Manufacturer trial: 100 mg/day for 6 weeks. Beta-glucan immune studies generally use 100–250 mg/day.
Active Compound Carboxymethylated, water-soluble beta-1,3/1,6-glucan from baker's/brewer's yeast (Saccharomyces cerevisiae). CM-Glucan™ Nu is manufactured by Mibelle Biochemistry.

Benefits

Immune 'training' and resilience

Yeast beta-glucans prime innate immune cells; randomized trials of the class show enhanced vaccine antibody responses and increased salivary IgA, supporting CM-Glucan Nu's immune-support positioning.

Fewer/shorter upper-respiratory symptoms

Across the beta-glucan literature, supplementation is associated with reduced cold/flu symptom days, consistent with the brand's resilience claim.

Airborne-allergy symptom relief (manufacturer trial)

Mibelle reports a placebo-controlled trial in which CM-Glucan Nu improved pollen-allergy quality of life and symptoms. This specific trial is not PubMed-indexed.

Mechanism of action

1

Innate immune training (dectin-1)

Beta-1,3/1,6-glucans bind dectin-1 and complement receptors on innate immune cells, 'training' them for faster, more measured responses to later challenges.

2

Mucosal IgA support

Yeast beta-glucan increases secretory IgA at mucosal surfaces, a first line of defense in the airways.

Clinical trials

1
CM-Glucan Nu Pollen-Allergy Trial (manufacturer)

Randomized, double-blind, placebo-controlled, 100 mg/day for 6 weeks. Published in a non-PubMed-indexed journal.

Adults with seasonal pollen allergy

Improved allergy-related quality of life and symptoms versus placebo. Treat as manufacturer evidence pending indexed publication.

2
Yeast beta-glucan class evidence

Independent randomized trials and a systematic review of yeast/fungal beta-glucans.

Healthy adults; vaccination and cold/flu cohorts

Enhanced influenza-vaccine antibody response, increased salivary IgA, and reduced upper-respiratory symptom days — the evidence base behind the beta-glucan class.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated; yeast beta-glucan has self-affirmed GRAS status.
Mild gastrointestinal upset possible.
Those with yeast allergy should choose carefully, though purified glucan is largely protein-free.
Autoimmune conditions: immune-activating supplements should be used under clinician guidance.

Important Drug interactions

Immunosuppressant medications: theoretical opposition to therapy given immune-activating action — use only with clinician guidance.
No other well-documented interactions.

Frequently asked questions about CM-Glucan™ Nu (Carboxymethyl Yeast Beta-Glucan)

What is CM-Glucan Nu?

It is an oral, water-soluble yeast beta-glucan from Mibelle that acts as an immune 'trainer', marketed for resilience and seasonal-allergy comfort. Its own trial is in a non-indexed journal, but the wider yeast beta-glucan class has solid randomized immune evidence.

How is beta-glucan supposed to help immunity?

Beta-1,3/1,6-glucans bind receptors like dectin-1 on innate immune cells and 'train' them to respond faster and more efficiently, and they raise mucosal IgA. Trials of the class show better vaccine responses and fewer cold/flu symptom days.

What is CM-Glucan Nu used for?

CM-Glucan Nu is researched primarily for Immune Support and Respiratory Health. Yeast beta-glucans prime innate immune cells; randomized trials of the class show enhanced vaccine antibody responses and increased salivary IgA, supporting CM-Glucan Nu's immune-support positioning.

What is the recommended dosage of CM-Glucan Nu?

The clinically studied dose is Manufacturer trial: 100 mg/day for 6 weeks. Beta-glucan immune studies generally use 100–250 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is CM-Glucan Nu safe, and does it have side effects?

For most healthy adults, CM-Glucan Nu is well tolerated at studied doses. Reported effects can include: Generally well tolerated; yeast beta-glucan has self-affirmed GRAS status. Mild gastrointestinal upset possible. It may also interact with some medications. CM-Glucan Nu is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does CM-Glucan Nu interact with any medications?

Possible interactions include: Immunosuppressant medications: theoretical opposition to therapy given immune-activating action — use only with clinician guidance. No other well-documented interactions. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for CM-Glucan Nu?

NutraSmarts rates the evidence for CM-Glucan Nu as Limited (2 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Moreno ML, Nieves CJ, Hebert K, Vivas CA, Rivero-Mendoza D, Colee J, et al. Yeast Beta-Glucan Enhances Antibody Response Following Influenza Vaccination - A Double-Blind, Randomized, Placebo-Controlled Pilot Trial. Journal of Dietary Supplements. 2025;22(5):795-810. doi: 10.1080/19390211.2025.2539876.PubMedUsed to support: A randomized controlled trial showing yeast beta-glucan supplementation enhanced antibody response to influenza vaccination — human immune-support evidence for the beta-glucan class behind CM-Glucan Nu.
  2. Vlassopoulou M, Yannakoulia M, Pletsa V, Zervakis GI, Kyriacou A Effects of fungal beta-glucans on health - a systematic review of randomized controlled trials. Food & Function. 2021;12(8):3366-3380. doi: 10.1039/d1fo00122a.PubMedUsed to support: A systematic review of randomized trials of fungal/yeast beta-glucans on health outcomes, giving the broader evidence context for CM-Glucan Nu's immune positioning.
  3. McFarlin BK, Carpenter KC, Davidson T, McFarlin MA Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. Journal of Dietary Supplements. 2013;10(3):171-83. doi: 10.3109/19390211.2013.820248.PubMedUsed to support: A randomized trial in which baker's yeast beta-glucan increased salivary IgA and reduced cold/flu symptom days — classic human support for yeast beta-glucan immune effects.